Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2011, Pages 147-152

  Tashkin, Donald P ^a   Varghese, Santosh T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; FEV 1; Formoterol; Tiotropium

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; MOMETASONE FUROATE; PLACEBO; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CLASSIFICATION; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEX DIFFERENCE; SMOKING; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AREA UNDER CURVE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEX FACTORS; SMOKING;

EID: 79251594946     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.07.003     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Available at:, [Accessed 01.08.07]. http://www.goldcopd.com/Guidelineitem.asp%3Fl1%3D2%26l2%3D1%26intId%3D989.
2. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004, 17(1):35-39.
3. Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006, 100(11):1925-1932.
4. Tashkin D.P., Donohue J.F., Mahler D.A., Huang H., Goodwin E., Schaefer K., et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009, 103(4):516-524.
5. Tashkin D.P., Littner M., Andrews C.P., Tomlinson L., Rinehart M., Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008, 102(4):479-487.
6. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26(2):214-222.
7. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129(3):509-517.
8. Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009, 6(1):17-25.
9. de Torres J.P., Casanova C., Hernandez C., Abreu J., Aguirre-Jaime A., Celli B.R. Gender and COPD in patients attending a pulmonary clinic. Chest 2005, 128(4):2012-2016.
10. Connett J.E., Murray R.P., Buist A.S., Wise R.A., Bailey W.C., Lindgren P.G., et al. Changes in smoking status affect women more than men: results of the lung health study. Am J Epidemiol 2003, 157(11):973-979.
11. Kanner R.E., Connett J.E., Altose M.D., Buist A.S., Lee W.W., Tashkin D.P., et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The lung health study. Am J Respir Crit Care Med 1994, 150(4):956-961.
12. Soriano J.B., Sin D.D., Zhang X., Camp P.G., Anderson J.A., Anthonisen N.R., et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007, 131(3):682-689.
13. Vestbo J., Soriano J.B., Anderson J.A., Calverley P., Pauwels R., Jones P. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 2004, 98(11):1045-1050.
14. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
15. Tashkin D., Celli B., Kesten S., Lystig T., Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT(R) trial. Respir Med 2010 April 23, [Epub ahead of print].
16. Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363(9410):731-733.
17. Kharitonov S.A., Barnes P.J. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004, 1(3):191-199.
18. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352(19):1967-1976.
19. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167(1):24-31.
20. Van Overveld F.J., Demkow U., Gorecka D., De Backer W.A., Zielinski J. Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. J Physiol Pharmacol 2006, 57(Suppl. 4):273-282.
21. Moita J., Barbara C., Cardoso J., Costa R., Sousa M., Ruiz J., et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008, 21(1):146-151.
22. Tashkin D.P., Celli B., Kesten S., Lystig T., Mehra S., Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010, 35(2):287-294.
23. Rennard S.I., Serby C.W., Ghafouri M., Johnson P.A., Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996, 110(1):62-70.